Alzheimer's drug LEQEMBI under 6-Year safety watch in 3,000 patients
NCT ID NCT06810960
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 3,000 South Korean Alzheimer's patients taking LEQEMBI for up to 6 years to monitor safety, especially brain swelling or bleeding. Researchers will use real-world data from a national registry. The goal is to understand how often these side effects occur in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eisai Trial Site #1
RECRUITINGNutley, New Jersey, 07110, United States